Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. - Wikidata - wikimedia - TriplyDB

Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells.

Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells.

http://www.wikidata.org/entity/Q34321823

about

Biomedical and clinical promises of human pluripotent stem cells for neurological disorders Recent Progress in Stem Cell Therapy for Diabetic Nephropathy Induced Pluripotent Stem Cell as a New Source for Cancer Immunotherapy The Application of Human iPSCs in Neurological Diseases: From Bench to Bedside Modeling Kidney Disease with iPS Cells Stem cell technology for tendon regeneration: current status, challenges, and future research directions Regenerative medicine: Current therapies and future directions The immune response of stem cells in subretinal transplantation Mesenchymal and induced pluripotent stem cells: general insights and clinical perspectives The Possible Future Roles for iPSC-Derived Therapy for Autoimmune Diseases The Dark Side of the Force - Constraints and Complications of Cell Therapies for Stroke Clinical implications of basic science discoveries: induced pluripotent stem cell therapy in transplantation--a potential role for immunologic tolerance Stem cells in retinal regeneration: past, present and future Induced pluripotent stem cell-derived cardiomyocytes for cardiovascular disease modeling and drug screening Human embryonic stem cell-derived oligodendrocytes: protocols and perspectives Induction of pluripotency by defined factors Immunogenicity and tumorigenicity of pluripotent stem cells and their derivatives: genetic and epigenetic perspectives The potential for immunogenicity of autologous induced pluripotent stem cell-derived therapies Concise review: making and using clinically compliant pluripotent stem cell lines Stem cell imaging: from bench to bedside Considerations for pre-clinical models and clinical trials of pluripotent stem cell-derived cardiomyocytes Induced pluripotent stem cell (iPSCs) and their application in immunotherapy Modeling AEC-New approaches to study rare genetic disorders Pluripotent stem cells in regenerative medicine: challenges and recent progress Can pluripotent stem cells be used in cell-based therapy?The immunogenicity of cells derived from induced pluripotent stem cells Gene therapy on the move Induced pluripotent stem cells in hematology: current and future applications Modelling kidney disease with CRISPR-mutant kidney organoids derived from human pluripotent epiblast spheroids Stem Cell Therapy: A Prospective Treatment for Alzheimer's Disease Potential of Induced Pluripotent Stem Cells (iPSCs) for Treating Age-Related Macular Degeneration (AMD)Present and future challenges of induced pluripotent stem cells Banking on iPSC--is it doable and is it worthwhile Efficient reprogramming of naïve-like induced pluripotent stem cells from porcine adipose-derived stem cells with a feeder-independent and serum-free system Controlling immune rejection is a fail-safe system against potential tumorigenicity after human iPSC-derived neural stem cell transplantation Toward pluripotency by reprogramming: mechanisms and application The Power and the Promise of Cell Reprogramming: Personalized Autologous Body Organ and Cell Transplantation Technology advancement for integrative stem cell analyses Perspectives of gene combinations in phenotype presentation Bone Tissue Engineering: Past-Present-Future.

P2860

Q21284798-F2C2E679-7E56-404C-823A-41A1A0E75B33 Q26740433-DEB4AA07-12FB-40DE-B728-641A38F4FDC0 Q26750579-A5855992-DA30-44E9-A2FE-D9D0AFC550C4 Q26765876-17F95719-C4D6-4C27-BE0C-B089198E334D Q26770384-20C834A4-F595-43CD-ABD4-CDA56D090558 Q26771642-0A3FAB77-14A3-42B6-8C44-A3BF6EFDC942 Q26776380-B600E1B4-2654-4B4F-A2A4-1E74506DBCFF Q26781292-44D6F72F-327C-4603-A33D-C7D625CFE158 Q26785623-C1B169B1-F8E2-4CD5-83CE-FADE00C44686 Q26799472-85456BA4-FD36-4ED4-8954-26B2FCACC257 Q26800181-39F67374-D9C7-437A-A987-4142E5B200AC Q26824632-9859917E-B47A-401C-AE3B-4C3DF5C09A29 Q26828014-1D76A938-B2FD-4D23-95D5-05D9FC1C69FE Q26828408-5C687B3A-2286-489E-A791-42D85E50D099 Q26829414-582512C0-C7B0-4FC7-B03E-274D4FC9E277 Q26830425-AD140BD6-B125-457E-95B6-8717AD642136 Q26849530-B1E811DC-CF6B-40B9-99D2-0B80B9670C2B Q26851666-9FD3D45F-6AA4-4720-97BC-0DD2EFBE8740 Q26852128-AD3433AD-5E94-405F-B6A4-25B8B048A3DE Q26861615-C0B7DBA3-DC8F-407C-A209-479E366C55A0 Q26865173-42918872-E113-4DA1-9229-A8CC6C291A66 Q26996540-2BA9E604-640C-4B53-9CD6-81D23715CEBA Q26996543-4347FF1F-8470-40DE-84A0-6E8C1A23630C Q26999292-10BF5C43-6437-4866-A20F-3FF7573B0596 Q27002327-9961C918-EAAF-465C-AB09-3C31494D1549 Q27003999-B5B54B05-1808-44FE-B2F6-F7BD0893FCD4 Q27007012-EF27999C-3C32-4658-849E-5FB4858D2B87 Q27016090-26F50288-B36C-4B10-921D-2D1B5FCFFDD6 Q27319887-47CCB18C-1039-4933-BE8C-F70C95F0685C Q28069506-BC9F5863-3D58-4D74-8517-B786F7B8F572 Q28077285-DDB7BBA4-9180-409A-AED0-140444673AB2 Q28082747-6AA9A224-893A-4FAA-BC84-3F20645DA308 Q28254023-A6919715-C62F-4DEA-9284-6B70BA9A9C7F Q28538854-79F5E1B3-D7A9-4890-B5D5-AA43F943EE33 Q28543575-E8E9EC30-E8EE-4CA2-BE57-4FCFA1A3EC50 Q28833688-12390B57-92C6-4727-A82E-CDFFD9BC2F18 Q28973616-BC6E3089-72D1-4AB5-9757-4E39210DADFA Q30397631-21CCD1C3-5975-44B3-B3E6-CA59A7EA6F24 Q30450809-497AD148-15FA-4451-A52B-098398454736 Q33363234-DAE9F280-D823-4E7E-ABA5-CA8C68F00710

P2860

Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells.

http://www.wikidata.org/entity/Q34321823

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Negligible immunogenicity of t ...... otent or embryonic stem cells.

@ast

Negligible immunogenicity of t ...... otent or embryonic stem cells.

@en

Negligible immunogenicity of t ...... otent or embryonic stem cells.

@nl

type

label

Negligible immunogenicity of t ...... otent or embryonic stem cells.

@ast

Negligible immunogenicity of t ...... otent or embryonic stem cells.

@en

Negligible immunogenicity of t ...... otent or embryonic stem cells.

@nl

prefLabel

Negligible immunogenicity of t ...... otent or embryonic stem cells.

@ast

Negligible immunogenicity of t ...... otent or embryonic stem cells.

@en

Negligible immunogenicity of t ...... otent or embryonic stem cells.

@nl

P1433

Q34321823-A49A155B-2F32-412E-B084-5135464EAFA9

P1476

Q34321823-70BD4CD9-FB65-4EED-A9D8-0BA195D606EB

P2093

Q34321823-00B3B7B6-A41F-403E-9619-3F524D25A2E4

Q34321823-3031B527-0DAF-477A-B77A-C9790F09C3FF

Q34321823-3A4D916D-A16E-47B3-8F89-362BA97C951E

Q34321823-438572A5-DC5B-4A81-9CBA-BF2D6B0D3435

Q34321823-5D90FAAC-C92E-4CA1-BAFD-B1A1943D20EE

Q34321823-762518A8-48B6-42CF-AD43-720AB7333666

Q34321823-80933425-ECF3-4DB5-9A81-E17ABF16ECA7

Q34321823-82404B6D-FDE5-4388-A2F3-7EC652A327D5

Q34321823-AE1823B8-42D0-485F-8728-3077E54A21C2

Q34321823-C0737228-6C65-4FEB-A695-5BBA8F0041D4

P2860

Q34321823-0F96810F-BD6D-4D15-A624-F683014E1507

Q34321823-134CCF1D-6E61-4EA0-B4D1-1019F1D457B8

Q34321823-13ED57DE-6380-4B48-8DB6-1371C4B7225B

Q34321823-1AD5B613-D2E9-4BEB-ACF4-E5204D117544

Q34321823-3083168C-1C21-4900-94EF-D7EB7785A4F0

Q34321823-36D216A0-2922-48E5-BA1B-0C1E84C777F8

Q34321823-4E706E71-ED35-4D7E-B569-52F46BC0F1F0

Q34321823-59249E7A-1A1C-4B1C-81EF-CC8C60B0C1C4

Q34321823-66F3FE66-998B-471B-93D3-2F874CFAF58F

Q34321823-6BE06CD3-28BF-4309-A3C2-6B2DA4F0C9D7

P2888

Q34321823-21CBF50C-8362-41EF-A409-2A4C26B6DA41

P304

Q34321823-1510136C-81FA-4E28-969C-15CEF64305CF

P31

Q34321823-B94569A9-2EC6-45EB-B483-B4215202FDD8

P356

Q34321823-0A6BB702-B101-49CE-915D-19AB2CC24CEA

P407

Q34321823-28B3FDB1-38C8-4140-99C3-A47ED9B9FAD9

P433

Q34321823-933C42F8-2ACD-46AB-B500-A3B5A66D2F6E

P478

Q34321823-34D2DE3E-C249-4A93-9BA3-4C1451688BC3

P577

Q34321823-9C41CA28-EF2D-4D09-AFE7-1825A0D6269B

P5875

Q34321823-65CE2F6D-71C8-42B8-AB5E-17F5A435CB7F

P6179

Q34321823-75FF2BEC-E003-4439-9996-0FA18FF6BA53

P698

Q34321823-AA0E27F2-07E1-4307-B8B2-75080DA44716

P356

P1433

P1476

Negligible immunogenicity of t ...... otent or embryonic stem cells.

@en

P2093

Akemi Shimada

http://www.w3.org/2001/XMLSchema#string

Akira Nifuji

http://www.w3.org/2001/XMLSchema#string

Hisashi Ideno

http://www.w3.org/2001/XMLSchema#string

Masahiro Uda

http://www.w3.org/2001/XMLSchema#string

Masumi Abe

http://www.w3.org/2001/XMLSchema#string

Mayumi Sugiura

http://www.w3.org/2001/XMLSchema#string

Miki Nakamura

http://www.w3.org/2001/XMLSchema#string

Misato Sunayama

http://www.w3.org/2001/XMLSchema#string

Ryoko Araki

http://www.w3.org/2001/XMLSchema#string

Shunsuke Ando

http://www.w3.org/2001/XMLSchema#string

P2860

Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors

A severe combined immunodeficiency mutation in the mouse

The ground state of embryonic stem cell self-renewal

Derivation of completely cell culture-derived mice from early-passage embryonic stem cells

Generation of mouse induced pluripotent stem cells without viral vectors

Immunogenicity of induced pluripotent stem cells

Somatic coding mutations in human induced pluripotent stem cells

Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin

Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells

Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease

P2888

P304

100-104

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NATURE11807

http://www.w3.org/2001/XMLSchema#string

P407

P433

7435

http://www.w3.org/2001/XMLSchema#string

P478

494

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

234098512

http://www.w3.org/2001/XMLSchema#string

P6179

1012678761

http://www.w3.org/2001/XMLSchema#string

P698

23302801

http://www.w3.org/2001/XMLSchema#string